• 1. Lipase-catalyzed green synthesis of enantiopure atenolol
  Bharat Prasad Dwivedee,Saptarshi Ghosh,Jayeeta Bhaumik,Linga Banoth,Uttam Chand Banerjee RSC Adv. 2015 5 15850
• 2. Facile fabrication of a recyclable nanobiocatalyst: immobilization of Burkholderia cepacia lipase on carbon nanofibers for the kinetic resolution of a racemic atenolol intermediate
  Surbhi Soni,Bharat Prasad Dwivedee,Uttam Chand Banerjee RSC Adv. 2018 8 27763

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenylacetamides

4-(3-Chloro-2-hydroxypropoxy)benzeneacetamide (Atenolol Impurity D): An Overview of a Key Pharmaceutical Intermediate

4-(3-Chloro-2-hydroxypropoxy)benzeneacetamide, also known as Atenolol Impurity D (CAS No. 115538-83-5), is a significant compound in the pharmaceutical industry, particularly in the context of drug impurity analysis and quality control. This compound is an important intermediate in the synthesis and production of Atenolol, a widely used β-adrenergic blocking agent. Understanding the properties, synthesis, and analytical methods for 4-(3-Chloro-2-hydroxypropoxy)benzeneacetamide is crucial for ensuring the safety and efficacy of pharmaceutical products.

Atenolol Impurity D is a byproduct that can form during the synthesis of Atenolol. Its presence in the final drug product can affect the drug's purity, stability, and therapeutic efficacy. Therefore, rigorous analytical methods are employed to detect and quantify this impurity. Recent advancements in analytical techniques, such as high-performance liquid chromatography (HPLC) and mass spectrometry (MS), have significantly improved the detection and quantification of 4-(3-Chloro-2-hydroxypropoxy)benzeneacetamide.

The chemical structure of 4-(3-Chloro-2-hydroxypropoxy)benzeneacetamide consists of a benzene ring substituted with an acetamide group and a chlorohydrin moiety. The presence of the chlorohydrin group makes this compound highly reactive and prone to forming various impurities during synthesis. This reactivity is both a challenge and an opportunity in pharmaceutical research, as it allows for the development of new synthetic pathways and impurity control strategies.

In terms of its physical properties, 4-(3-Chloro-2-hydroxypropoxy)benzeneacetamide is a white crystalline solid with a melting point ranging from 100 to 105°C. It is soluble in common organic solvents such as methanol, ethanol, and acetone but has limited solubility in water. These properties make it suitable for various purification techniques, including recrystallization and column chromatography.

The synthesis of 4-(3-Chloro-2-hydroxypropoxy)benzeneacetamide typically involves several steps. One common approach is to start with 4-hydroxybenzeneacetamide, which is then reacted with epichlorohydrin to form the desired product. The reaction conditions, including temperature, pressure, and catalysts, play a crucial role in determining the yield and purity of the final product. Recent studies have explored alternative synthetic routes to improve the efficiency and reduce the formation of unwanted impurities.

In addition to its role as an impurity in Atenolol, 4-(3-Chloro-2-hydroxypropoxy)benzeneacetamide has also been studied for its potential biological activities. Some preliminary research suggests that this compound may have antimicrobial properties, although further investigation is needed to confirm these findings. The study of such impurities not only helps in improving drug quality but also opens up new avenues for drug discovery.

The regulatory landscape for pharmaceutical impurities is stringent, with organizations such as the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) setting strict guidelines for impurity levels in drug products. The presence of even trace amounts of impurities like 4-(3-Chloro-2-hydroxypropoxy)benzeneacetamide can lead to regulatory non-compliance and potential safety issues. Therefore, continuous monitoring and control of these impurities are essential throughout the drug development process.

In conclusion, 4-(3-Chloro-2-hydroxypropoxy)benzeneacetamide (Atenolol Impurity D) is a critical compound in the pharmaceutical industry due to its role as an impurity in the synthesis of Atenolol. Understanding its chemical properties, synthesis methods, and analytical techniques is essential for ensuring drug quality and safety. Ongoing research into this compound continues to advance our knowledge and improve pharmaceutical manufacturing processes.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)